The breast cancer resistance protein (BCRP) is abundant in the placenta and protects the fetus by limiting placental drug penetration. We hypothesize that pregnancyspecific hormones regulate BCRP expression. Hence, we examined the effects of progesterone (P 4 ) and 17β-estradiol (E 2 ) on BCRP expression in the human placental BeWo cells. P 4 and E 2 significantly increased and decreased BCRP protein and mRNA, respectively. Likewise, treatment with P 4 and E 2 respectively increased and decreased fumitremorgin C-inhibitable mitoxantrone efflux activity of BeWo cells. Reduction in BCRP expression by E 2 was abrogated by the estrogen receptor (ER) antagonist ICI 182,780. However, the progesterone receptor (PR) antagonist RU 486 had no effect on P 4 -mediated induction of BCRP. P 4 together with E 2 further increased BCRP protein and mRNA, compared with P 4 treatment alone. This combined effect on BCRP expression was abolished by RU 486 or ICI 182,780 or both. Further analysis revealed that E 2 significantly decreased ERβ mRNA, and strongly induced PR B mRNA in a dosedependent manner, but had no effect on PR A and ERα. P 4 alone had no significant effect on mRNA of ERα, ERβ, PR A and PR B . E 2 in combination with P 4 increased PR B mRNA, but the level of induction was significantly reduced compared with E 2 treatment alone.
Introduction
The breast cancer resistance protein (BCRP) is the second member (gene symbol ABCG2) of the subfamily G of the large ATP-binding cassette (ABC) transporter superfamily (1, 9, 25) . BCRP is highly expressed in many normal tissues, including the epithelium of the small intestine and the liver canalicular membrane (22). Therefore, in addition to conferring resistance in cancer cells to chemotherapeutic agents such as mitoxantrone, topotecan and methotrexate (8, 9, 25, 36), BCRP has been shown to mediate apically directed drug transport, and play a significant role in absorption, distribution, and elimination of BCRP substrates (4, 19, 21, 32, 35) . Of interest is that BCRP is also abundantly expressed in the apical membrane of placental syncytiotrophoblasts (22) . Whereas the precise physiologic role of BCRP in the placenta is still unclear, existing data suggest that BCRP may protect the fetus against toxic substances/drugs and metabolites by extruding them across the placental barrier. For example, Bcrp1, the murine homolog of BCRP, has been shown to significantly alter fetal distribution of topotecan, a BCRP substrate. The fetus/plasma ratio of topotecan was increased 2-fold in pregnant mice treated with the BCRP inhibitor GF120918 as compared with the vehicle-treatment control (19) .
Distribution of drugs that are BCRP substrates across the placenta therefore may be altered by factors that can influence BCRP expression in the placenta. Several recent studies have shown that pregnancy can affect expression and function of ABC transporters. For instance, expression of P-glycoprotein (P-gp) protein in human placenta at early gestational stages (13 -14 weeks) was found to be 2 -45 times higher than that at late gestational stages (38 -41 weeks) (13, 23) . Expression and function of multidrug resistance protein 2 (Mrp2) in the liver of pregnant rats decreased to 50% of that of nonpregnant control rats (5) . Thus, the protection of fetuses and drug disposition in general can be influenced by pregnancy, through changing the expression and function of these transporters. A recent study by Mathias et al. (23) showed that BCRP expression in human placenta did not change significantly with gestational age. Since these studies were preliminary with limited tissue samples, and substantial variation in BCRP expression (mRNA and protein) was observed, more detailed analysis is needed.
To date, little is known about the molecular mechanism by which expression of ABC transporters in the placenta is altered by pregnancy. Progesterone (P 4 ) and 17β-estradiol (E 2 ) are the two most important steroid hormones produced by the human placenta during pregnancy. Estrogens, including E 2 , play important roles in regulating the growth, development, and differentiation of many reproductive tissues. P 4 is believed to be indispensable for the maintenance of pregnancy. Since the concentrations of E 2 and P 4 continuously increase throughout the course of pregnancy, we hypothesized that E 2 and P 4 play a significant role in regulating expression of ABC transporters in human placenta.
Recent studies have indeed demonstrated that E 2 is an important determinant in the regulation of BCRP expression in cancer cells by transcriptional or post-transcriptional mechanisms (10, 11, 17) . The effects of P 4 and, particularly, the combined effects of E 2 and P 4 on BCRP expression have not been reported.
In the present study, we have systematically analyzed the effects of P 4 and E 2 on expression and efflux function of BCRP in the model human placental BeWo cells, which express high levels of endogenous BCRP (2) . We found that E 2 by itself decreased BCRP expression and P 4 increased BCRP expression. P 4 in combination with E 2 further increased BCRP expression compared with P 4 treatment alone. The effects of E 2 and P 4 on expression of progesterone receptor A (PR A ), progesterone receptor B (PR B ), estrogen receptor α (ERα) and estrogen receptor β (ERβ) have also been investigated to explore the possible contribution of these steroid hormone nuclear receptors in regulating BCRP expression in BeWo cells. These studies found that some of the steroid hormone nuclear receptors could be involved in the regulation of BCRP in BeWo cells. Our findings provide new insights into the regulation of BCRP in the human placenta by pregnancy.
Materials and Methods
Materials. Progesterone (P-8783), 17β-estradiol (E-2758) and 17β-hydroxy-11β- [4- dimethylamino phenyl]-17α- [1-propynyl] No effects of the vehicle on cell viability, BCRP protein and mRNA expression, the plasma membrane localization of the transporter, and mitoxantrone efflux activity were observed at this concentration. 
SDS-Polyacrylamide Gel Electrophorsis and Immunoblotting.
The protein samples of whole cell lysates (20 µg each lane) were subjected to immunoblotting using BXP-21
(1:500 dilution), a BCRP-specific monoclonal antibody (mAb) (Kamiya Biomedical, Seattle, WA) as previously described (15) with the exception that the secondary antibody, goat anti-mouse HRP-conjugated antibody (Bio-Rad) was used at 1:5,000 dilution. For detection of β-actin, a mAb specific for human β-actin (Sigma) was used as primary antibody at 1:50,000 dilution and the goat anti-mouse HRP-conjugated antibody (BioRad) was used as secondary antibody at 1:25,000 dilution. Relative BCRP protein levels
were determined by densitometric analysis of the immunoblots using the NIH Scion
Image software (Scion Corp., Frederick, MD). β-actin was used as an internal control. decreased BCRP protein expression to 1.7-fold of the vehicle controls (Fig. 5C ).
Confocal
Effects of P 4 and E 2 on BCRP mRNA. We then examined whether the effects of P 4 and E 2 on BCRP protein expression were due to changes on BCRP mRNA levels. (Fig. 6) . RU 486 at 10 times molar excess to P 4 (2.5 × 10 -5 M RU 486 versus 2.5 × 10 -6 M P 4 ) also did not influence the inductive effect of P 4 on BCRP mRNA (Fig. 3C) . RU 486 and ICI 182, 780 themselves had no effect on BCRP mRNA expression (data not shown). min did not increase the activity (Fig. 7) . With all three accumulation times, treatment with 10 -5 M P 4 or 10 -7 M E 2 significantly increased or decreased the FTC-inhibitable MX efflux activity of the BeWo cells, respectively (Fig. 7) , and accumulation for 60 min seems to produce the most significant difference, as compared with the vehicle control.
Effects of P 4 and E
Therefore, an accumulation time of 60 min was used in all of the subsequent efflux experiments. As shown in M P 4 in combination with 10 -8 M E 2 was significantly greater than the activity of the cells treated with 10 -5 M P 4 alone. These findings are consistent with the protein and mRNA data ( Fig. 5 and Fig. 6 ). The addition of 10 -5 M RU 486 had no effect on P 4 -mediated stimulation of MX efflux ( Table 1) . or P 4, or a combination of both, the same as described for determining protein expression.
Effects of E
Endogenous expression of PR A , PR B , ERα and ERβ mRNA in untreated BeWo cells was detected by real-time PCR at 37.1 ± 0.7, 37.6 ± 0.5, 35.0 ± 0.6, and 35.6 ± 0.4 cycles, respectively, under the current assay conditions. The relative changes of mRNA levels of these receptors upon hormone treatment were then determined and are summarized in 
Discussion
The present study examines the effects of P 4 and E 2 on BCRP expression in BeWo cells. We found that P 4 significantly increased BCRP protein only at a relatively high concentration 10 -5 M (Fig. 2A) . The plasma P 4 concentration at term was reported to be approximately 0.7 × 10 -6 M and the intracellular P 4 concentrations in placenta were about 12 times greater than those in maternal plasma (20). Hence 10 -5 M P 4 could be achieved in the placenta at term. This concentration is much greater than the binding affinity of P 4 to a classical PR (7). Moreover, RU 486, even at 10 times molar excess, did not inhibit the inductive effect of P 4 (Fig. 3) . These results suggest that it is unlikely that induction of BCRP by The plasma E 2 concentration during pregnancy increases steadily to around 0.8 × 10 -7 M at term (3, 20) . At concentrations observed during pregnancy (10 -8 and 10 -7 M), E 2 significantly decreased BCRP protein (Fig. 4A ). This decrease was abolished by ICI 182,780 (Fig. 4C) , suggesting that down-regulation of BCRP by E 2 is mediated by ER.
Male-predominant expression of Bcrp1 in rat kidney has been reported (34). The authors showed that castration had no effect on Bcrp1 mRNA in rat kidney; however, Bcrp1 mRNA in the kidneys of ovariectomized female rats was significantly higher than that of control females, indicating that male-predominant expression of Bcrp1 in rat kidneys is likely caused by the absence of the suppressive effects of female-sex hormones such as E 2 . Male-predominant expression of human BCRP and mouse Bcrp1 in liver has also been demonstrated (24). These in vivo data seem to support our in vitro findings with respect to down-regulation of BCRP by E 2 .
We demonstrated for the first time the combined effects of P 4 and E 2 on BCRP expression. It is of considerable interest that E 2 at subthreshold doses (10 -9 and 10 -8 M)
further increased P 4 -mediated induction of BCRP, even at 10 -6 M P 4, which by itself showed little effect ( Fig. 2A and Fig. 5A ). This finding suggests that placental BCRP expression could be affected by pregnancy, even at earlier gestational stages when the P 4 concentrations are low. Since E 2 at 10 -8 M with 10 -5 M P 4 significantly induced PR B mRNA 2.2-fold (Table 2) , this further increase in BCRP expression is possibly mediated by E 2 -induced synthesis of PR B . The combination of 10 -7 M E 2 with 10 -5 M P 4 decreased, rather than increased, BCRP expression to the levels of P 4 treatment alone (Fig. 5 ). This could be explained by the fact that E 2 -induced synthesis of PR B was significantly diminished by 10 -7 M E 2 compared with 10 -8 M E 2 (Table 2) . Hence, both a non-classical PR (when P 4 was used alone) and a classical PR (when P 4 and E 2 were used together) may be involved in P 4 -mediated up-regulation of BCRP. E 2 at 10 -8 M induced PR B mRNA 7.5-fold. The decrease in E 2 -mediated induction of PR B in the presence of P 4 is likely due to the widely observed suppressive effect of P 4 on E 2 action (28). The addition of RU 486 or ICI 182,780, or both, abolished this further increase in BCRP protein by the combination of P 4 and E 2 ( Fig. 5C) , further suggesting that endogenous expression of PR B in BeWo cells is low, and thus PR B exerts its function only after it is induced by E 2 through ER.
The effects of P 4 and E 2 on BCRP mRNA in general corresponded well to the effects on BCRP protein (Fig. 6 ), suggesting that P 4 and E 2 regulate BCRP expression, at least in part, by a transcriptional mechanism. However, the possibility of a posttranscriptional mechanism cannot be excluded (17) . We consistently observed a significant increase and decrease of the FTC-inhibitable MX efflux activity of BeWo cells treated with 10 -5 P 4 and10 -7 M E 2 , respectively, compared with the vehicle controls ( Fig. 7 and Table 1 The reason for this apparent discrepancy is currently unknown. Genetic alterations may occur in cells after prolonged culture. Hence, BeWo cells only within 8 passages after purchase were used in this study.
In summary, the present study suggests that 1) P 4 and E 2 respectively up-regulates and down-regulates BCRP expression in BeWo cells; 2) The interaction between P 4 and E 2 , through PR B and ERβ, may play a significant role in the regulation of BCRP in BeWo cells; 3) Steroid hormones, for example P 4 , may function through a classical or non-classical PR, or both pathways, in response to specific endocrine status during pregnancy.
Further studies are needed to elucidate the molecular mechanisms by which BCRP expression is regulated by P 4 and E 2 in BeWo cells. Such studies will help understand how pregnancy affects drug distribution across the placenta. It should be pointed out that the BeWo cell line is not exactly the same as the placental trophoblast with respect to the expression of ABC transporters, and therefore, care should be taken when extrapolating the data obtained in this cell line to in vivo human subjects. The relative BCRP mRNA levels associated with vehicle controls are set as 1. The data shown are mean ± S.E. from four independent experiments. The differences in BCRP mRNA levels are statistically significant: * p < 0.05; ** p < 0.01 as compared with the vehicle controls using one-way ANOVA analysis. ∆ p < 0.05 as compared with E 2 treatment alone using Student's t-test. The BeWo cells were treated with P 4 and/or E 2 , and the effects of hormone treatment on the FTC-inhibitable MX efflux activity of the BeWo cells were determined as described in "Materials and Methods". The MX efflux activity of the vehicle control cells are set as 100%. The data shown are mean ± S.E. from three independent experiments. The differences in MX efflux are statistically significant using Student's t-test: * p < 0.05, ** p < 0.01 as compared with the vehicle controls; # p < 0.05 as compared with P 4 treatment alone; ∆ p < 0.05 as compared with E 2 treatment alone. The BeWo cells were treated with P 4 and/or E 2 in the absence and presence of ICI 182, 780 and the effects of hormone treatment on mRNA levels of PR A , PR B , ERα and ERβ were determined as described in "Materials and Methods". Relative mRNA levels normalized to β-actin are presented. The relative mRNA levels of the vehicle controls are set as 1. The data shown are mean ± S.E.
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from four independent experiments. The differences in mRNA levels are statistically significant: * p < 0.05; ** p < 0.01 as compared with the vehicle controls using Student's t-test. 
